Comparison of standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy for H elicobacter pylori infection: Patients' compliance and bacterial eradication rates

Objective To compare the patients' compliance with and the efficacy of existing treatments for H elicobacter pylori eradication, including moxifloxacin‐based triple therapy, sequential treatment and the standard treatment. Methods Patients with H . pylori infection were randomly assigned to three therapy groups. The triple therapy ( MML ) group was given moxifloxacin 400 mg/day, metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 10 days. The sequential treatment ( AL‐CML ) group was administrated amoxicillin 1 g b.i.d. and lansoprazole 30 mg b.i.d. for the first 5 days, followed by clarithromycin 500 mg b.i.d., metronidazole 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for the second 5 days. The standard treatment ( CAL ) group received amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days. The eradication rates were evaluated by per‐protocol ( PP ) analysis and intention‐to‐treat ( ITT ) analysis. Results The eradication rates were 87.1, 85.9 and 85.2% by PP analysis and 87.1, 84.9 and 84.2% by ITT analysis in the MML , AL‐CML and CAL group, respectively, and patients' compliance rates were 98.2, 96.5 and 97.1%, respectively. There were no significant differences in treatment efficacy and compliance rates in the MML , AL‐CML and CAL groups ( P  > 0.05). Conclusions The present study revealed that standard triple therapy, sequential therapy and moxifloxacin‐based triple therapy are all effective treatment regimens in terms of H . pylori eradication rates and compliance with therapy in T urkey.